INHALE-1: A 26-week Primary Treatment Phase,with 26-week Extension, Open-label, RandomizedClinical Trial Evaluating the Efficacy and Safety ofAfrezza?? Versus Rapid-acting Insulin AnalogInjections, Both in Combination with a Basal Insulin,in Pediat

Medicine & Life Sciences

1. faropenem medoxomil 100%
2. Short-Acting Insulin 98%
3. Insulin 45%
4. Safety 38%
5. Randomized Controlled Trials 22%
6. Injections 19%
7. Therapeutics 10%